Investigating the cytotoxicity of iron oxide nanoparticles in in vivo and in vitro studies.

In recent years, iron oxide nanorods find a lot of applications including drug delivery, cell separation, hyperthermia and magnetic resonance imaging. In this study the cytotoxicity of iron oxide nanorods was evaluated based on mouse fibroblast cell behavior and wistar rat's liver and kidney function. At first for modification, nanorods were added to Dulbecco's modified Eagle's medium (DMEM) which contained a lot of sources of vitamins, amino acids, proteins in Fetal Bovine Serum (FBS). The MTT assay was employed for evaluating the toxic effects of 200 and 400 µg/mL modified and non-modified iron oxide nanorods on L929 mouse fibroblast cells in a 24h period. Changes in cell granularity and size as well as cell cycle were investigated using flow cytometry. Moreover liver and kidney function test and serum iron level measurement were performed 24h after the injection of modified iron oxide nanorods via the tail peripheral vein of wistar rats. Results indicated that greater concentration of modified iron oxide nanorods had no significant effect on cell viability while greater concentration of non-modified iron oxide nanorods significantly decreased cell viability. Modified iron oxide nanorods did not have significant effects on cell cycle. The results of liver and kidney function tests did not differ significantly while a significant increase in serum iron level was observed. After H&E staining of slices, there were no changes on morphology of rat's kidney and liver cells. This study suggests that short-time use of 200 and 400 µg/mL iron oxide nanorods are probably safe. Further studies are needed for investigation of toxic effects of different concentrations, coatings, and exposure time periods of iron oxide nanorods.

Tumor suppression effects of myoepithelial cells on mice breast cancer.

Several studies have assumed that myoepithelial cells (MECs) loss may contribute to epithelial tumor induction and/or progression. We adopted an in vitro assay and a syngeneic mice breast cancer model with histological and molecular characteristics resembling human lesions to evaluate tumor suppression effects of MECs. Flow cytometric, cell viability, blood chemistry, transmission electron microscope, immunohistochemistry and qRT-PCR assays were performed at the end of the study. We demonstrated that MECs could significantly suppress the viability of cancer cells at different time points (P<0.05). At the end of the fourth and fifth weeks, treated mice had smaller tumor volume compared with control animals. Average tumor volume was significantly less in treated groups than control group at days 21 (0.38±0.19 vs. 1.99±0.13 cm3), 28 (0.57±0.3 vs. 2.5±0.37 cm3) and 35 (0.7±0.35 vs. 2.65±0.4 cm3) after tumor cell injection (P<0.05). No hematological, hepatocellular, and renal toxicities were seen in MECs treated groups. Ultrastructural features revealed severe relationship between adjacent tumoral cells and loose interconnections of neoplastic cells in treated group. Immunohistochemical examinations of breast tumors showed high p63 and low alpha-smooth muscle actin protein expression in treated mice compared to control (P<0.05). MRNA expressions of TNF-α, smooth muscle-myosin heavy chain, connexin 43, and maspin were significantly up-regulated in breast tumor tissues in treated group compared to control (P<0.05). VEGF and alpha-smooth muscle actin mRNA expression were reduced in treated animals (P<0.05). The present study highlighted the potential tumor suppression effects of MECs on breast cancer in a typical animal model.